{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T03:07:17Z","timestamp":1788923237351,"version":"build-2803163510"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.prp.2026.156372","type":"journal-article","created":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T16:26:35Z","timestamp":1771604795000},"page":"156372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["PD-L1 expression across urothelial carcinoma subtypes: A multicenter comparison of 22C3 and SP142 for clinical decision-making in the immunotherapy era"],"prefix":"10.1016","volume":"281","author":[{"given":"Juan Daniel Prieto","family":"Cuadra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina \u00c1lvarez","family":"P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pilar","family":"Gonz\u00e1lez-Peramato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juli\u00e1n","family":"Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"de Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia Garc\u00eda","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Zucchiatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Jos\u00e9 Lozano","family":"Le\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa Matas","family":"Rico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Isabel Hierro","family":"Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2026.156372_bib1","series-title":"Global Cancer Observatory: Cancer Today","author":"Ferlay","year":"2024"},{"key":"10.1016\/j.prp.2026.156372_bib2","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2016.02.028","article-title":"The 2016 WHO classification of tumours of the urinary system and male genital organs-part B: prostate and bladder tumours","volume":"70","author":"Humphrey","year":"2016","journal-title":"Eur. Urol."},{"key":"10.1016\/j.prp.2026.156372_bib3","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/his.13752","article-title":"Variant and new entities of bladder cancer","volume":"74","author":"Lopez-Beltran","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2026.156372_bib4","article-title":"Tumours of the urinary tract","volume":"8","author":"Raspollini","year":"2022"},{"key":"10.1016\/j.prp.2026.156372_bib5","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.eururo.2019.10.026","article-title":"Updated results of PURE-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.prp.2026.156372_bib6","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/his.13958","article-title":"Distinct genetic alterations and luminal molecular subtype in nested variant of urothelial carcinoma","volume":"75","author":"Weyerer","year":"2019","journal-title":"Histopathology"},{"key":"10.1016\/j.prp.2026.156372_bib7","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/14712598.2020.1733965","article-title":"Immunotherapy for urothelial cancer","volume":"20","author":"Cimadamore","year":"2020","journal-title":"Diagn. Pathol. \u2019S. Point view. Expert Opin. Biol. Ther."},{"issue":"1","key":"10.1016\/j.prp.2026.156372_bib8","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/JU.0000000000000761","article-title":"Histologic subtypes and response to PD-1\/PD-L1 Blockade in advanced urothelial cancer: a retrospective study","volume":"204","author":"Miller","year":"2020","journal-title":"J. Urol."},{"key":"10.1016\/j.prp.2026.156372_bib9","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11912-018-0693-y","article-title":"Emerging role of immunotherapy in advanced urothelial carcinoma","volume":"20","author":"Koshkin","year":"2018","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.prp.2026.156372_bib10","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.eururo.2018.06.019","article-title":"Frequent PD-L1 protein expression and molecular correlates in urinary bladder squamous cell carcinoma","volume":"74","author":"Udager","year":"2018","journal-title":"Eur. Urol."},{"key":"10.1016\/j.prp.2026.156372_bib11","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.humpath.2019.10.005","article-title":"Primary adenocarcinoma of the bladder lacks mismatch repair deficiency and demonstrates PD-L1 expression in tumor-infiltrating immune cells, with implications in both diagnosis and therapeutics","volume":"94","author":"Jones","year":"2019","journal-title":"Hum. Pathol."},{"key":"10.1016\/j.prp.2026.156372_bib12","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1097\/PAS.0000000000001264","article-title":"PD-L1 expression in urothelial carcinoma with predominant or pure variant histology","volume":"43","author":"Reis","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2026.156372_bib13","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.2147\/JIR.S499403","article-title":"The Benefits and Safety of Monoclonal Antibodies: Implications for Cancer Immunotherapy","volume":"18","author":"Zhang","year":"2025","journal-title":"J. Inflamm. Res"},{"key":"10.1016\/j.prp.2026.156372_bib14","first-page":"170","article-title":"Programmed death death ligand-1\/programmed death-1 inhibition therapy and programmed death ligand-1 expression in urothelial bladder carcinoma","volume":"5","author":"Yu","year":"2019","journal-title":"Chronic Dis. Transl. Med."},{"issue":"5","key":"10.1016\/j.prp.2026.156372_bib15","doi-asserted-by":"crossref","first-page":"357","DOI":"10.56434\/j.arch.esp.urol.20237605.42","article-title":"A Survival Model for Patients with Upper Tract Urothelial Carcinoma","volume":"76","author":"Chengliang","year":"2023","journal-title":"Arch. Espa\u00f1oles De. Urol. \u00eda"},{"issue":"5","key":"10.1016\/j.prp.2026.156372_bib16","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1007\/s00345-020-03498-0","article-title":"PD-L1 testing in urothelial bladder cancer: essentials of clinical practice","volume":"29","author":"Rouanne","year":"2021","journal-title":"World J. Urol."},{"key":"10.1016\/j.prp.2026.156372_bib17","first-page":"10","article-title":"PD-L1 immunoexpression and molecular characterization of histological subtypes in urothelial carcinoma","volume":"56","author":"Dawid de Vera","year":"2023","journal-title":"Rev. Espa\u00f1. Patol."},{"key":"10.1016\/j.prp.2026.156372_bib18","article-title":"Non-targeted Metabolomics Reveals the Potential Role of MFSD8 in Metabolism in Human Endothelial Cells","author":"Xiang","year":"2025","journal-title":"Mol. Biotechnol."},{"key":"10.1016\/j.prp.2026.156372_bib19","first-page":"261","article-title":"Aspectos pr\u00e1cticos sobre la determinaci\u00f3n de PD-L1 en el tratamiento de carcinoma urotelial. Consenso del grupo de uropatolog\u00eda de la SEAP","volume":"56","author":"L\u00f3pez-Beltr\u00e1n","year":"2023","journal-title":"Rev. Espa\u00f1. Patol."},{"key":"10.1016\/j.prp.2026.156372_bib20","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s13000-021-01151-x","article-title":"PD-L1 immunostaining: what pathologists need to know","volume":"16","author":"Akhtar","year":"2021","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.prp.2026.156372_bib21","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.3390\/jpm12071073","article-title":"Atlas of PD-L1 for pathologists: indications, scores, diagnostic platforms and reporting systems","volume":"12","author":"Marletta","year":"2022","journal-title":"J. Pers. Med"},{"issue":"2","key":"10.1016\/j.prp.2026.156372_bib22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pathol.2020.10.007","article-title":"Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation","volume":"53","author":"Paver","year":"2021","journal-title":"Pathology"},{"key":"10.1016\/j.prp.2026.156372_bib23","unstructured":"Keytruda: prescribing information. Hoddesdon, Merck Sharp & Dohme Limited. United Kingdom. \u3008https:\/\/www.ema.europa. eu\/en\/documents\/product-information\/keytruda-epar-product-information es.pdf\u3009."},{"key":"10.1016\/j.prp.2026.156372_bib24","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s00345-018-2264-0","article-title":"Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer","volume":"36","author":"Soria","year":"2018","journal-title":"World J. Urol."},{"key":"10.1016\/j.prp.2026.156372_bib25","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1097\/PAI.0000000000000594","article-title":"Development of a PD-L1 complementary diagnostic immunohistochemistry assay (SP142) for atezolizumab","volume":"27","author":"Vennapusa","year":"2019","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"10.1016\/j.prp.2026.156372_bib26","unstructured":"VENTANA PD-L1 (SP142) Assay Interpretation Guide for Urothelial Carcinoma. VENTANA PD-L1 (SP142) Assay package insert for manufacturer contact information. 2020 Ventana Medical Systems, Inc. and Roche."},{"key":"10.1016\/j.prp.2026.156372_bib27","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1097\/PAS.0000000000001084","article-title":"PD-L1 immunohistochemistry assay concordance in urothelial carcinoma of the bladder and hypopharyngeal squamous cell carcinoma","volume":"42","author":"Hodgson","year":"2018","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.prp.2026.156372_bib28","doi-asserted-by":"crossref","first-page":"722","DOI":"10.5858\/arpa.2017-0555-OA","article-title":"Analytical validation and clinical utility of an immunohistochemical programmed death lingand-1 diagnostic assay and combined tumor and immune cell scoring algorithm for durvalumab in urothelial carcinoma","volume":"143","author":"Zjac","year":"2019","journal-title":"Arch. Pathol. Lab Med"},{"key":"10.1016\/j.prp.2026.156372_bib29","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ejca.2018.11.007","article-title":"Performance of the Food and Drug Administration\/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratifcation for first-line use of atezolizumab and pembrolizumab","volume":"106","author":"Eckstein","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.prp.2026.156372_bib30","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00428-018-2453-7","article-title":"RUSSCORSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer","volume":"473","author":"Zavalishina","year":"2018","journal-title":"Virchows Arch."},{"key":"10.1016\/j.prp.2026.156372_bib31","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.eururo.2018.11.002","article-title":"PD-L1 antibody comparison in urothelial carcinoma","volume":"75","author":"Rijnders","year":"2019","journal-title":"Eur. Urol."},{"issue":"1","key":"10.1016\/j.prp.2026.156372_bib32","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1038\/s41598-020-58351-6","article-title":"Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes","volume":"10","author":"Li","year":"2020","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.prp.2026.156372_bib33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.56434\/j.arch.esp.urol.20237603.27","article-title":"Atypical recurrent renal cell carcinoma of the ipsilateral ureter showing typical symptoms of upper urinary tract urothelial carcinoma: a case report and literature review","volume":"76","author":"Minxiong","year":"2023","journal-title":"Arch. Espa\u00f1. Urol."},{"key":"10.1016\/j.prp.2026.156372_bib34","unstructured":"PD-L1 IHQ 22C3 PharmDx Interpretation Manual -- Urothelial Carcinoma. Dako --- Agilent Technologies. \u3008https:\/\/www.agilent.com\/cs\/library\/usermanuals\/public\/ 29276 22C3 pharmdx uc interpretation manual us\u3009."},{"key":"10.1016\/j.prp.2026.156372_bib35","article-title":"PD-L1 testing in urothelial carcinoma: analysis of a series of 1401 cases using both the 22C3 and SP142 assays","volume":"28","author":"Evans","year":"2022","journal-title":"Patol. Oncol. Res"},{"key":"10.1016\/j.prp.2026.156372_bib36","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1007\/s00428-018-2453-7","article-title":"RUSSCO-RSP comparative study of immunohistochemistry diagnostic assays for PD-L1 expression in urothelial bladder cancer","volume":"473","author":"Zavalishina","year":"2018","journal-title":"Virchows Arciv"},{"key":"10.1016\/j.prp.2026.156372_bib37","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00428-019-02610-z","article-title":"Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays","volume":"475","author":"Schwamborn","year":"2019","journal-title":"Virchows Arch."},{"issue":"9","key":"10.1016\/j.prp.2026.156372_bib38","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1093\/bioinformatics\/btac122","article-title":"SEPA: signaling entropy-based algorithm to evaluate personalized pathway activation for survival analysis on pan-cancer data","volume":"38","author":"Li","year":"2022","journal-title":"Bioinformatics"},{"key":"10.1016\/j.prp.2026.156372_bib39","article-title":"Long acting injectables for the treatment of prostate cancer","volume":"100","author":"Dimple Modi","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826000233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033826000233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T19:24:11Z","timestamp":1774121051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033826000233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":39,"alternative-id":["S0344033826000233"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2026.156372","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 expression across urothelial carcinoma subtypes: A multicenter comparison of 22C3 and SP142 for clinical decision-making in the immunotherapy era","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2026.156372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier GmbH.","name":"copyright","label":"Copyright"}],"article-number":"156372"}}